BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11850228)

  • 1. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
    Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
    Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
    Jordan VC
    Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800.
    Sourla A; Luo S; Labrie C; Bélanger A; Labrie F
    Endocrinology; 1997 Dec; 138(12):5605-17. PubMed ID: 9389549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
    Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
    Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
    Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
    Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
    Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice.
    Couillard S; Labrie C; Gauthier S; Merand Y; Singh SM; Candas B; Labrie F
    Int J Cancer; 2000 Feb; 85(3):424-9. PubMed ID: 10652436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
    Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
    Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
    Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice.
    Luo S; Sourla A; Labrie C; Gauthier S; Merand Y; Belanger A; Labrie F
    Endocrinology; 1998 May; 139(5):2645-56. PubMed ID: 9564882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptors as therapeutic targets in breast cancer.
    Ariazi EA; Ariazi JL; Cordera F; Jordan VC
    Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice.
    Roy J; Couillard S; Gutman M; Labrie F
    Breast Cancer Res Treat; 2003 Oct; 81(3):223-9. PubMed ID: 14620917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.